BioMarin
Develops rare-disease medicines across enzyme therapies, metabolic disorders, and skeletal conditions.
$64.67
After-hours close+0.02 (+0.02%)
At close$64.65(−0.98%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $1.38 | — | — |
| Aug 2026 | $0.95 | $1.20 | +26.7% |
| May 2026 | $0.94 | $0.76 | −19.1% |
| Feb 2026 | $0.17 | −$0.24 | −241.7% |
| Oct 2025 | −$0.15 | $0.12 | +180.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Aug 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Oct 2016 | |||
| Aug 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 26, 2026 | $1.38 | — | — | $1.03B | — | — |
| Aug 6, 2026 | $0.95 | $1.20 | +26.7% | $932.0M | $989.7M | +6.2% |
| May 4, 2026 | $0.94 | $0.76 | −19.1% | $752.5M | $766.0M | +1.8% |
| Feb 23, 2026 | $0.17 | −$0.24 | −241.7% | $833.7M | $874.6M | +4.9% |
| Oct 27, 2025 | −$0.15 | $0.12 | +180.0% | $823.5M | $776.1M | −5.7% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 4, 2025 | ||||||
| May 1, 2025 | ||||||
| Feb 19, 2025 | ||||||
| Oct 29, 2024 | ||||||
| Aug 5, 2024 | ||||||
| Apr 24, 2024 | ||||||
| Feb 22, 2024 | ||||||
| Nov 1, 2023 | ||||||
| Jul 31, 2023 | ||||||
| Apr 26, 2023 | ||||||
| Feb 27, 2023 | ||||||
| Oct 26, 2022 | ||||||
| Aug 3, 2022 | ||||||
| Apr 27, 2022 | ||||||
| Feb 23, 2022 | ||||||
| Oct 27, 2021 | ||||||
| Jul 28, 2021 | ||||||
| Apr 29, 2021 | ||||||
| Feb 25, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 4, 2020 | ||||||
| Apr 29, 2020 | ||||||
| Feb 26, 2020 | ||||||
| Oct 23, 2019 | ||||||
| Aug 1, 2019 | ||||||
| Apr 25, 2019 | ||||||
| Feb 21, 2019 | ||||||
| Oct 25, 2018 | ||||||
| Aug 2, 2018 | ||||||
| Apr 25, 2018 | ||||||
| Feb 22, 2018 | ||||||
| Oct 26, 2017 | ||||||
| Aug 2, 2017 | ||||||
| May 4, 2017 | ||||||
| Feb 23, 2017 | ||||||
| Oct 27, 2016 | ||||||
| Aug 4, 2016 | ||||||
| Apr 28, 2016 | ||||||
| Feb 25, 2016 | ||||||
| Oct 29, 2015 | ||||||
| Aug 3, 2015 | ||||||